Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What&rsquo;s new?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

345

HTML

3234

Figures (1-1)

170

Tables (1-4)

155

Sum=3904

Nov 28, 2007 (publication date) through Aug 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 28, 2007; 13(44): 5877-5887
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5877

Table 4 Panitumumab, Phase II and III studies

	Pts (n)	RR (%)	PFS	Naive	Phase
Alone³⁰	148	10	-	No	II
Alone vs BSC³¹	463	10	8 wk	No	III
Alone³²	91	8	8 wk	No	II
IFL + Panitumumab vs FOLFIRI + Panitumumab³³	19 24	46 42	5.6 mo 10.9 mo	Yes	II

Pts: Patients; RR: Response rate; PFS: Progression free survival; OS: Overall survival; mo: months; BSC: Best supportive care.

Citation: Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new? World J Gastroenterol 2007; 13(44): 5877-5887
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5877.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5877